Prostatype Genomics

Interview with Aktiespararna
Prostatype Genomics CEO Fredrik Rickman is interviewed by Aktiespararna. Click on the link below to access the interview.
Aktiespararna – interview with Prostatype Genomics 21 May 2025

Interview with Redeye
Prostatype Genomics CEO Fredrik Rickman is interviewed by Redeye. Click on the link below to access the interview.
Redeye – interview with Prostatype Genomics 23 May 2025

Summary of the Rights Issue

• Existing shareholders have received one (1) unit right for each share held on the record date 19 May 2025. One (1) unit right entitles the holder to subscribe for one (1) unit in the Company.
• Each unit consists of four (4) new shares and three (3) warrants of series TO5.
• The subscription price in the Rights Issue is SEK 4.00 per unit, corresponding to SEK 1.00 per share. warrants of series TO5 are issued free of charge.
• Upon full subscription in the Rights Issue, Prostatype Genomics will initially receive approximately SEK 27.3 million before deduction of issue costs.
• The subscription period in the Rights Issue runs until and including 4 June 2025. Please note that different banks apply different closing dates for the subscription period, so shareholders are advised to check with their bank for the specific closing date.
• The Rights Issue is covered by pre-subscription commitments and guarantee commitments of a total of approximately 81 percent. The guarantee commitments consist partly of so-called top-down underwritings and partly of so-called bottom underwritings.
• One (1) warrant of series TO5 entitles the holder to subscribe for one (1) new share in the Company during the period 3 September 2025 until and including 17 September 2025 at an exercise price of 30% discount of the 20-day volume-weighted average price prior to the first day of the exercise period. However, no less than SEK 0.10 and no higher than SEK 1.50 per share. Warrants of series TO5 are expected to be admitted to trading on Nasdaq First North Growth Market in close connection with the registration of the Rights Issue with the Swedish Companies Registration Office and the conversion of BTU to ordinary shares and warrants.
• In order to meet the interest for participating in the Rights Issue and thereby further strengthening the Company’s financial position, Board has been authorized by the annual general meeting to issue additional units through so-called over-allotment in the event of oversubscription of the Rights Issue. The authorization is limited to approximately 15 percent of the total amount of units in the Rights Issue and an issue in accordance with the authorization shall be made on corresponding terms as the Rights Issue.

Time plan for the Rights Issue

• 30 May 2025: trading in unit rights ends
• 4 June 2025: subscription period ends
• Around 5 June 2025: press release with outcome of Rights Issue is announced

Information to investors under the Screening of Foreign Direct Investment Act (2023:560)
As the Company conducts activities worthy of protection in accordance with the Screening of Foreign Direct Investment Act (2023:560), certain investments in the Rights Issue may require examination by the Inspectorate for Strategic Products. For more information, please visit the Swedish Inspectorate for Strategic Products' website, www.isp.se or contact the Company.

Advisors
Navia Corporate Finance AB and Gemstone Capital ApS are financial advisors and Bookrunners in connection with the Rights Issue. Advokatfirman Lindahl is the legal advisor. Nordic Issuing AB is the issuing agent.

For more information about the Rights Issue, please contact:
Navia Corporate Finance AB
E-mail: info@naviacf.se
Website: www.naviacorporatefinance.com

or

Gemstone Capital ApS
E-mail: info@gemstonecapital.com
Website: www.gemstonecapital.com

For more information about the Company, please contact:
Fredrik Rickman, CEO Prostatype Genomics AB
Telephone: +46 (0)73 049 77 01
E-mail: fredrik.rickman@prostatypegenomics.com

Certified Adviser
DNB Carnegie
Telephone: +46 (0)73 856 42 65
E-mail: certifiedadviser@carnegie.se

About Prostatype Genomics
Prostatype® is a genomic test that is available to patients and treating urologists as a complementary decision basis for the question of treatment or no-treatment of prostate cancer. The test was developed by a leading research group at Karolinska Institute and is provided by Prostatype Genomics AB. The Company’s Certified Adviser is DNB Carnegie.